GIVLAARI (givosiran), the first GalNAc‐siRNA drug targeting hepatocyte aminolevulinate synthase 1, has been approved by the FDA for the treatment of acute hepatic porphyria.[32] Our previous work deploying a GalNAc‐siRNA conjugate targeting HK2 obtained unprecedented anti‐HCC efficacy in vivo.[12] ALDOA is absent or rarely expressed in normal hepatocytes, as it is a muscle‐type aldolase, but it is highly expressed in HCC; therefore, it is a promising therapeutic target for HCC. The gene discussed is HK2; the disease is Acute hepatic porphyria.